ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Educational Symposium

SGLT2 Inhibitors: Should We Put Them in the Water of Patients with CKD?

November 04, 2021 | 12:45 PM - 01:45 PM

Location: Simulive, Virtual Only

Session Description

Studies of sodium glucose cotransporter 2 (SGLT2) inhibitors have demonstrated beneficial effects on kidney-related, cardiovascular, and heart failure outcomes. Clinical trials have enrolled patients with CKD with and without type 2 diabetes, patients with heart failure, and patients with CKD and eGFR as low as 25–30 mL/min/1.73 m2. The benefits of SGLT2 inhibitors have also been evident in emerging real-world data. The majority of patients in the clinical trials were already optimally treated with ACE inhibitors or ARBs at baseline.

The high prevalence of CKD worldwide means the need is urgent for medications that decrease CKD progression and improve cardiovascular outcomes. This symposium outlines the clinical trial and real-world evidence for using SGLT2 inhibitors in patients with CKD. In addition, practice points are shared for the safe and effective use of these agents.

Support is provided by an educational grant from AstraZeneca Pharmaceuticals.

Learning Objective(s)

  • Describe clinical trial and real-world evidence supporting SGLT2 inhibitor use in patients with CKD with and without diabetes
  • Discuss the safe and effective use of SGLT2 inhibitors for optimizing kidney-related and cardiovascular outcomes for patients with CKD

Learning Pathway(s)

  • Diabetes and Metabolism
  • Hypertension and CVD


  • Katie E. Cardone, PharmD, RPh, FASN


  • Introduction
    12:45 PM - 12:55 PM
    Katie E. Cardone, PharmD, RPh, FASN
  • Kidney and Cardiovascular Protection with SGLT2 Inhibitors Across the Spectrum of CKD
    12:55 PM - 01:20 PM
    Meg Jardine, MBBS, PhD
  • Clinical Pearls About the Use of SGLT2 Inhibitors for Patients with CKD
    01:20 PM - 01:45 PM
    Joshua J. Neumiller, PharmD